Skip to main content

Table 2 Baseline characteristics in belatacept cohort by status for graft failure at 12 and 24 months censored for death

From: Microvascular inflammation is a risk factor in kidney transplant recipients with very late conversion from calcineurin inhibitor-based regimens to belatacept

Patient characteristics All patients (N = 30) Functioning graft at 12 months (N = 23) Graft failure at 12 months (N = 6) P value Functioning graft at 24 months (N = 18) Graft failure at 24 months (N = 9) P value
Age (y) 53.5 ± 26 54.0 ± 19 43 ± 23 0.302 51.5 ± 23 48 ± 28 0.940
Donor age (y) 48.0 ± 23 50.0 ± 26 44 ± 19 0.555 45 ± 26 48.5 ± 23 0.825
Gender (m/f) 20/10 15/8 4/2 1.000 12/6 5/4 0.683
Post-transplant diabetes 3/30 3/23 0/6 1.000 3/18 0/9 0.529
BMI 25.3 ± 4.1 24.9 ± 3.9 25.4 ± 6.6 0.511 24.1 ± 5.6 25.5 ± 5.6 0.194
Systolic BP (mmHg) 134 ± 17 138 ± 20 131.5 ± 30 0.384 136.5 ± 21 133 ± 16 0.348
Diastolic BP (mmHg) 84 ± 10 84 ± 10 84 ± 31 0.581 86 ± 11 84 ± 18 0.691
Time after transplantation (m) 127.5 ± 91.3 128 ± 130 127.5 ± 52.5 0.773 133.5 ± 135.5 126 ± 35 0.275
eGFR (mL/min) 22.5 ± 12 24.0 ± 13 19.0 ± 10 0.302 25.5 ± 12 18.0 ± 4 0.095
eGFR < 25 mL/min 17/30 12/23 5/6 0.354 8/18 8/9 0.042
Proteinuria (mg/g creatinine) 840 ± 1166 830 ± 950 1256 ± 3211 0.302 657 ± 1276 869 ± 2017 0.668
Living donor transplants 8/30 6/23 2/6 1.000 4/18 3/9 0.653
pancreas/kidney 2/30     
Immunosuppression
 Tacrolimus 22/30 15/23 6/6 0.148 13/18 6/9 1.000
 Cyclosporine A 8/30 8/23 0/6 0.148 5/18 3/9 1.000
 Mycophenolic acid 27/30 20/23 6/6 1.000 16/18 9/9 0.538
 Azathioprin 2/30 2/23 0/6 1.000 1/18 0/9 1.000
 Steroid 24/30 17/23 6/6 0.295 13/18 8/9 0.628
DSA 14/30 11/23 2/6 0.663 8/18 4/9 1.000
h/o any rejection 15/30 10/23 5/6 0.169 7/18 7/9 0.103
aTCMR 3/30 1/23 2/6 0.100 1/18 2/9 0.250
aABMR 6/30 4/23 2/6 0.575 2/18 4/9 0.136
Biopsy scores
 glomerular scarring (%) 30.5 ± 33 27 ± 31 42 ± 27 0.302 29 ± 27 32 ± 43 0.860
 cg 0.0 ± 3.0 0.0 ± 3.0 1.25 ± 3.0 0.694 0.0 ± 1.1 2.5 ± 3.0 0.232
 ct 1.0 ± 1.0 1.0 ± 1.0 1.0 ± 2.0 0.546 1.0 ± 1.0 1.0 ± 1.0 0.348
 ci 1.0 ± 1.0 1.0 ± 1.0 1.0 ± 2.0 0.477 1.0 ± 1.0 1.0 ± 1.0 0.253
 cv 2.0 ± 2.0 2.0 ± 2.0 1.5 ± 1.0 0.427 2.0 ± 3.0 2.0 ± 1.0 0.560
 mm 1.0 ± 2.0 1.0 ± 1.0 2.0 ± 1.5 0.071 0.0 ± 1.0 2.0 ± 1.5 0.067
 ah 3.0 ± 0.0 3.0 ± 0.0 3.0 ± 0.3 0.979 0.0 ± 1.0 3.0 ± 1.0 0.860
 g 0.0 ± 1.0 0.0 ± 1.0 0.0 ± 1.9 0.694 0.0 ± 1.0 0.0 ± 1.8 0.668
 t 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 2.0 0.384 0.0 ± 0.0 0.0 ± 1.0 0.322
 i 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 2.0 0.546 0.0 ± 0.0 0.0 ± 1.0 0.781
 v 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0 1.000 0.0 ± 0.0 0.0 ± 0.0 1.000
 ptc 0.0 ± 0.0 0.0 ± 0.0 0.5 ± 3.0 0.102 0.0 ± 0.0 0.0 ± 0.0 0.067
 C4d 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 1.0 0.655 0.0 ± 0.0 0.0 ± 0.0 0.820
 MVI sum score 0.0 ± 1.3 0.0 ± 1.0 1.25 ± 3.8 0.254 0.0 ± 0.0 2.0 ± 3.0 0.095
 MVI sum score 2 7/30 4/23 3/6 0.131 2/18 5/9 0.023
  1. Data were expressed as medians (interquartile range), or numbers
  2. BMI body mass index, BP Blood pressure, eGFR estimated glomerular filtration rate, DSA donor specific antibodies, h/o history of, aTCMR active T cell mediated rejection, aABMR active antibody-mediated rejection, MVI microvascular inflammation